US Zinc Prices Hold Steady in Early July as Pharmaceutical Demand and Supply Costs Support Market

The zinc powder market in the United States remained largely stable during the first half of July after posting firm gains throughout June. Zinc powder prices entered July on a balanced footing as steady procurement from pharmaceutical manufacturers offset the easing pace of buying seen after June's rally. Market participants reported that the earlier upward momentum had largely stabilized, with supply concerns continuing to support sentiment despite normal trading activity. Tight concentrate availability continued reliance on imported material, and disciplined supplier offers helped keep the zinc powder market firm, while buyers largely adopted routine purchasing strategies instead of aggressive restocking. According to ChemAnalyst, analysts expect zinc powder prices to remain on a gradual upward path during the second half of July as supply costs remain elevated and pharmaceutical demand stays healthy.

Demand from the pharmaceutical and healthcare sectors remained the primary pillar supporting the zinc powder market. Manufacturers producing pharmaceutical formulations, topical medicinal products, nutraceutical preparations, and healthcare formulations maintained consistent procurement schedules to support ongoing production requirements. Routine purchasing from generic drug manufacturers and contract manufacturing organizations helped sustain market activity, while healthcare distributors continued replenishing inventories at a measured pace. Although US zinc powder buyers avoided excessive stock-building, stable consumption from pharmaceutical applications prevented any meaningful decline in zinc powder demand and kept overall market sentiment balanced.

Supply conditions continued to provide firm support for the zinc powder market. Persistent zinc concentrate tightness and operational issues at several international smelters continued to restrict refined metal availability, supporting replacement costs for imported material. Since the U.S. zinc powder market remains heavily dependent on imported supplies, overseas pricing continued to influence domestic quotations. Additionally, the FDA's latest Generic Drug User Fee Amendments (GDUFA) update placed renewed attention on the cost structure facing API manufacturers, Drug Master File holders, and generic drug producers supplying the U.S. market. Updated fee requirements for DMF submissions and domestic as well as foreign API facilities increased regulatory cost considerations across the pharmaceutical supply chain, contributing to firmer production economics for zinc powder suppliers serving pharmaceutical applications.

June market activity provided the foundation for the current stability. Zinc powder prices strengthened steadily throughout June as supply remained constrained and pharmaceutical procurement improved. Buyers maintained regular purchasing while suppliers defended offers amid tight availability. Entering July, weekly assessments indicated that zinc powder prices had stabilized, reflecting a balanced market where consistent pharmaceutical demand matched available supply.

Looking ahead, analysts expect zinc powder prices to strengthen modestly during the second half of July. Stable pharmaceutical and healthcare demand, continued import dependence, elevated regulatory compliance costs, and persistent concentrate tightness are expected to keep the zinc powder market supported. While significant price spikes appear unlikely, suppliers are expected to maintain firm quotations as production economics remain elevated. The zinc powder outlook remains based on current market trends and is subject to changes in supply availability, pharmaceutical procurement activity, regulatory developments, and international trade conditions.